articaine hydrochloride; epinephrine bitartrate - Profile

What are the generic drug sources for articaine hydrochloride; epinephrine bitartrate and what is the scope of freedom to operate?

Articaine hydrochloride; epinephrine bitartrate is the generic ingredient in five branded drugs marketed by Hospira, Pierrel, Deproco, and Hansamed Inc, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for articaine hydrochloride; epinephrine bitartrate

US Patents:	0
Tradenames:	5
Applicants:	4
NDAs:	5

US Patents and Regulatory Information for articaine hydrochloride; epinephrine bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	079138-001	Jun 18, 2010		DISCN	No	No
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-001	Feb 26, 2010		RX	Yes	No
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-002	Feb 26, 2010		RX	Yes	Yes

Articaine Hydrochloride / Epinephrine Bitartrate: Investment Scenario and Fundamentals Analysis

Last updated: April 26, 2026

Articaine hydrochloride plus epinephrine bitartrate is an established local anesthetic and vasoconstrictor combination used for dental and other minor procedures. The investment profile is driven by (1) regulatory maturity and low technical differentiation in generics, (2) procurement scale through dental distributors and institutional formularies, and (3) a narrow set of value levers: device-adjacent packaging, dosing/concentration variants, and supply-chain reliability.

What is the product and where does it compete?

Indication and clinical role

The combination is used to provide local anesthesia while epinephrine reduces local blood flow to prolong anesthetic duration and reduce systemic absorption. Commercial demand is largely procedure-frequency driven through dentistry and outpatient minor procedures.

Typical market positioning

• “Dental local anesthetic cartridges” are the core commercial format.
• Formulations are usually marketed in multiple strengths or dosing schemes, with epinephrine concentration used to tune hemostasis and duration.

Competitive landscape

The competitive set typically includes:

• Multinational brand originators
• Generic manufacturers with ANDA-level equivalence
• Private-label and contract manufactured offerings for dental channels
• Supply-chain “availability premium” bidders during shortages

How do fundamentals look: demand, supply, and pricing?

Demand drivers

Key demand variables:

• Patient throughput in dental settings
• Managed care and dental benefit plan utilization trends
• Procedure mix (restorative, endodontic, surgical)
• Substitution stability: dentistry tends to remain on established anesthetic protocols unless formularies shift

Demand is generally resilient but not immune to utilization cycles.

Pricing structure and economics

The combination is usually commoditized. Core determinants of margin in mature markets:

• Generic price erosion after first entrants
• Tender pricing and distributor margin terms
• Availability and lot-level continuity (service level impacts distributor allocation)
• Active ingredient cost volatility (API market conditions)
• Packaging and shelf-life logistics

Investment implication: upside is usually created by scale, procurement discipline, and dependable supply rather than patent-protected pricing power.

Supply-side dynamics

Supply risks tend to dominate short-cycle price spikes:

• API and sterile fill-finish capacity constraints
• Quality system disruptions
• Regulatory inspections affecting release timelines
• Freight and cold-chain needs if packaging logistics require special handling (varies by product)

How strong is the IP position for articaine HCl / epinephrine bitartrate?

Patent reality check for investors

For mature local anesthetic combinations, the industry tends to converge on generic availability where exclusivity windows have expired. The investable question becomes:

• Is there any still-live regulatory exclusivity (rare in fully mature products)?
• Is there any meaningful formulation differentiation that can sustain a premium (typically difficult for direct injectables)?
• Are there device, packaging, or delivery system innovations that qualify for separate protection?

For a generic-dominated product category, the “IP moat” is usually replaced by:

• Manufacturing know-how
• Quality and regulatory history
• Distribution relationships
• Fast time-to-market for new concentrations/sizes

What is the regulatory and exclusivity framework that shapes returns?

Regulatory pathway

• Generic entrants generally rely on bioequivalence and sameness-of-substance standards for injectable local anesthetics.
• Corporate return models in this category often assume: price compression after approvals, then stabilization based on manufacturing reliability and channel penetration.

Exclusivity channels investors should model

Even when primary patents lapse, new approvals can create temporary windows through:

• Line extensions (dose/concentration, pack size)
• Orphan-like routes (unlikely here)
• Pediatric or additional exclusivities tied to labeling changes (rare for this category)
• 505(b)(2)-style pathways if a product has meaningful differences (generally harder for a fixed combination used as a standard of care)

Investment implication: for this product, exclusivity is usually incremental at best, not structural.

Where do buyers allocate budget: channels and contracting patterns?

Procurement channels

• Dental distributors and wholesaler networks
• Hospital outpatient procedure supply chains (less dominant than dental retail)
• Group purchasing organizations and dental service organizations
• Direct institutional contracting for recurring inventory

Contracting mechanics

• Shortlisting favors dependable supply and documentation readiness
• Price is central, but service level can break ties
• Reference pricing can compress premiums quickly

Investment implication: winning new share generally requires either low landed cost at scale or guaranteed availability during constrained supply periods.

What are the practical investment theses by strategy?

Thesis A: Scale generic manufacturer with service-level advantage

What you buy:

• A mature product with predictable core demand
• A distribution network that allocates based on availability and fulfillment

What drives returns:

• Lower unit costs through high batch utilization
• Reduced quality-cost drag via robust sterility assurance and low deviation rates
• Channel share gains via reliable shipment schedules

Key risks:

• Price erosion from multiple entrants
• QA/regulatory events that delay release
• API supply disruptions

Thesis B: Platform operator for line extensions and pack-size variants

What you buy:

• The ability to respond to tender-driven product format preferences

What drives returns:

• Faster and broader SKU coverage
• Superior shelf-life and logistics (where applicable)
• Faster regulatory submission cycles

Key risks:

• Limited differentiation means rapid commoditization
• Competitors can replicate format and compress margins

Thesis C: Integration into distribution and contracting for recurring dental volumes

What you buy:

• Stability of demand contracts and predictable procurement

What drives returns:

• Negotiated pricing and inventory planning
• Reduced working-capital volatility through contract structures

Key risks:

• Contract rollovers can shift costs to buyers or suppliers
• Inventory mismatches in sudden utilization shifts

What fundamentals matter most: manufacturing quality, regulatory track record, and cost?

Manufacturing quality and sterility assurance

For injectable local anesthetics, investor-grade manufacturing assessment should focus on:

• Batch-to-batch consistency and deviation rates
• Sterility assurance and container closure integrity performance
• Stability program strength and out-of-spec incident history
• Sterile fill-finish capacity and change-control maturity

Regulatory track record

Key indicators:

• Inspection outcomes and corrective action closures
• Timeliness of annual reports and variation submissions
• Historical product holds and recalls (if any)

Cost structure

A defensible cost advantage is usually built from:

• Stable API supply terms (or long-term sourcing)
• High utilization of fill-finish lines
• Yield improvements in sterile processing
• Procurement leverage on consumables and packaging

How do you diligence market risk: shortages, competition, and formularies?

Shortages

Shortage conditions typically raise temporary pricing and distributor pull-through. The investment issue is:

• Do you have manufacturing throughput and release readiness to capture the window?

Competition and entrants

Generic market dynamics are pressure-tested by:

• Number of approved competitors
• Relative ability to scale volume
• Speed of subsequent entrants after first movers

Formulary and guideline inertia

Clinical protocol inertia can stabilize demand once a product is stocked. But decisions still move through:

• Committee-driven switching
• Tender cycles
• Insurance and reimbursement adjustments

What upside and downside scenarios should an investor model?

Upside scenario (service-level premium + SKU expansion)

Assumptions:

• No major regulatory disruptions
• Competitive pricing holds through stable channel supply
• Gradual share gains in dental distributor tenders

Typical financial outcome:

• Higher volume growth with manageable price erosion
• Margin protection through cost-down and better batch throughput

Base scenario (commoditized pricing, volume-driven returns)

Assumptions:

• Price erosion continues but stabilizes
• Competition increases but does not collapse supply pricing
• Demand tracks dental procedure activity

Outcome:

• Moderate, predictable returns driven by scale and cost leadership

Downside scenario (quality incident or capacity constraint)

Assumptions:

• Release delays or compliance action disrupt shipments
• API or sterile fill-finish constraints cause missed tender allocations
• Competitors capture contracted volumes

Outcome:

• Revenue loss from availability gaps
• Higher remedial costs and potential product holds

Key takeaways for capital allocation

• Articaine hydrochloride plus epinephrine bitartrate is a mature, largely generic-driven category where returns hinge on manufacturing execution, supply reliability, and distribution contracting more than on patent leverage.
• The most investable edge is service-level performance: consistent release, low deviation rates, and dependable tender fulfillment.
• Market expansion is likely to come from SKU coverage and pack-size variants aligned with procurement preferences, not from major clinical breakthroughs.
• Financial models should be structured around commoditized pricing and cyclical volume, with explicit sensitivity to quality/regulatory events and capacity constraints.

FAQs

1. Is this product typically patent-protected in a way that supports premium pricing?

No. The category is generally mature, with market power shifting to generics based on scale, quality, and supply reliability rather than sustained exclusivity.

2. What creates the most margin upside for manufacturers?

Unit cost reduction through high utilization, lower sterile processing friction, and packaging/logistics optimization, combined with winning tenders through dependable availability.

3. How do shortages affect investment returns?

Shortages can create short-cycle pricing and volume pull-through if a manufacturer can release product on time and meet distributor allocations.

4. What are the most material operational risks?

Quality system disruptions, sterility assurance failures, release delays, and sterile fill-finish capacity constraints, alongside API sourcing interruptions.

5. Where does growth most plausibly come from in this category?

From expanding SKU assortment (concentrations/pack sizes aligned with tender needs), increasing distributor and institutional penetration, and capturing contract renewals through service-level performance.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
[3] National Library of Medicine. (n.d.). DailyMed. https://dailymed.nlm.nih.gov/dailymed/